Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
Burning Mouth Syndrome
About this trial
This is an interventional treatment trial for Burning Mouth Syndrome
Eligibility Criteria
Inclusion Criteria: burning mouth syndrome; oral pain that recurs daily for > 2 hours per day for > 3 months; pain with burning quality and felt superficially in the oral mucosa; oral mucosa appears normal oral clinical examination, including sensory tests, is normal; Exclusion Criteria: pregnancy; oral mucosal lesions; systemic diseases such as diabetes, anemia, deficiency of vitamin B1, B2, B6, B12, Fe, Zinc, and folic acid; gastroesophageal reflux; previous head and neck radiotherapy; Sjogren's disease; allergies; candidiasis; unstimulated saliva flow < 0.25 ml/min and stimulated flow < 1.0 ml/min will be excluded;
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Placebo Comparator
No Intervention
Experimental
Experimental
Experimental
Experimental
topical placebo tablet
control
topical clonazepam tablet
oral alpha-lipoic acid capsule
topical phytotherapic capsaicin gel
local photobiomodulation
magnesium silicate placebo tablet three times a day for 21 days
artificial saliva
2.0 mg Clonazepam tablet three times a day for 21 days
300 mg alpha-lipoic acid capsule twice a day for 60 days
0.025 mg capsaicin gel 4 times a day for 14 days
Photobiomodulation with wavelength of 810 nm, power of 0.6 W, power density of 1.2 W/cm², beam area of 0.5 cm², and energy of 6 J.